Medicilon(SH:688202) Zheng Quan Zhi Xing·2025-08-29 17:01Group 1 - The core viewpoint of the article is that Shanghai Medicy Bio-Pharmaceutical Co., Ltd. plans to increase its expected daily related transactions for the year 2025, which has been approved by the board of directors and is deemed necessary for the company's normal business operations [1][2][8] - The expected amount for the increased daily related transactions is 20 million yuan, which does not require shareholder meeting approval according to relevant regulations [2][3] - The independent directors and the supervisory board have unanimously agreed that the increase in expected daily related transactions aligns with the company's operational needs and does not harm the interests of shareholders, particularly minority shareholders [2][8] Group 2 - The main categories of the expected daily related transactions include sales of new drug research services and the provision of experimental animal services, which are considered normal business activities [7] - The company will sign written agreements with related parties for these transactions, ensuring that the pricing is fair and based on market conditions [7] - The related parties involved include Weishen Pharmaceutical (Nantong) Co., Ltd. and Puxin (Putian Xiuyu) Biological Co., Ltd., with specific details on their business operations and ownership structures provided [5][6]